Novo Nordisk snatches Dicerna
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
LSP and EQT merge to create top-10 investment firm
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Novartis inks US-$1.3bn deal with Dunad Therapeutics
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Agomab Therapeutics to acquire Origo Biopharma
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Sofinnova Capital X Fund closed at 472m
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
Curevac withdraws MAA of CVnCoV
German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Delivering on Europe´s Green Deal EFIB 2021 in Vienna
Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.
COVID-19 immunisation set to get FDA EUA
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
BioNTech investigates cancer vaccine BNT122 in Phase II trial
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
Advent France Biotechnology launches 86m fund